Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at higher risk for AKI and current risk predictor scores that are based on clinical and demographic information are inadequate. Therefore, a diagnostic test for predicting AKI risk in this clinical context would assist clinicians to optimize surgical strategy and postoperative care to prevent CSA-AKI occurrence and improve patient outcomes. The primary purpose of this study is to measure the association between baseline expression of senescence markers in blood using SenesceTest and the occurrence of CSA-AKI post surgery.
Study Type
OBSERVATIONAL
Enrollment
186
Duke University
Durham, North Carolina, United States
Development of stage 1 or higher postoperative AKI as defined by the AKIN classification (stage 1- ≥ 0.5 mg/dL absolute or ≥ 50% relative rise in peak SCr over the baseline)
Time frame: 48-72 hours
Number of Participants who suffered postoperative stroke
Time frame: 30 days
Number of Participants who suffered cognitive decline
Time frame: 30 days
Number of Participants requiring prolonged mechanical ventilation (for longer than 24h)
Time frame: 30 days
Number of Participants with : cardiac arrest, perioperative myocardial infarction and perioperative ventricular dysfunction.
Time frame: 30 days
Number of Participants with cardiac arrest
Time frame: 30 days
Number of Participants with perioperative myocardial infarction
Time frame: 30 days
Number of Participants with perioperative ventricular dysfunction.
Time frame: 30 days
Number of Participants with postoperative deep sternal wound infection
Time frame: 30 days
Number of Participants with postoperative thoracotomy infection
Time frame: 30 days
Number of Participants with postoperative sepsis.
Time frame: 30 days
Number of Participants in need for renal replacement therapy
Time frame: 30 days
Number of Participants who progressed to end stage renal disease.
Time frame: 30 days
Death
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.